CN111655703B - 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 - Google Patents
肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 Download PDFInfo
- Publication number
- CN111655703B CN111655703B CN201880088159.XA CN201880088159A CN111655703B CN 111655703 B CN111655703 B CN 111655703B CN 201880088159 A CN201880088159 A CN 201880088159A CN 111655703 B CN111655703 B CN 111655703B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- liver
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004185 liver Anatomy 0.000 title abstract description 27
- 229940002612 prodrug Drugs 0.000 title abstract description 7
- 239000000651 prodrug Substances 0.000 title abstract description 7
- -1 nucleoside cyclic phosphate compound Chemical class 0.000 title description 26
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 title description 10
- 229960000684 cytarabine Drugs 0.000 title description 7
- 229910019142 PO4 Inorganic materials 0.000 title description 6
- 239000010452 phosphate Substances 0.000 title description 6
- 239000002777 nucleoside Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 15
- 201000007270 liver cancer Diseases 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 239000012442 inert solvent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000012453 solvate Substances 0.000 abstract description 10
- 150000004677 hydrates Chemical class 0.000 abstract description 5
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract description 2
- 238000011319 anticancer therapy Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- 238000006243 chemical reaction Methods 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000007787 solid Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 14
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 238000002390 rotary evaporation Methods 0.000 description 13
- 229910052736 halogen Inorganic materials 0.000 description 12
- 150000002367 halogens Chemical class 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 125000001589 carboacyl group Chemical group 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 4
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 4
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 102000044284 human CYP3A4 Human genes 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004712 monophosphates Chemical group 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- IERHLVCPSMICTF-CCXZUQQUSA-N [(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-CCXZUQQUSA-N 0.000 description 1
- 238000011298 ablation treatment Methods 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003609 aryl vinyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000010227 extrahepatic metabolism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
一类基于肝脏特异性递送技术(肝递送)(Liver specific Delivery(LSD))的抗癌前体药物核昔环磷酸醋化合物及其应用被公开,具体地,提供了式(I)化合物及其异构体、可药用盐、水合物、溶剂化物、相应的药物组合物以及所述化合物单独或与其它抗癌药物联合在抗癌中的应用,特别是在治疗肝癌(HCC)中的应用。
Description
技术领域
本发明涉及基于肝脏特异性递送技术(肝递送)(Liver Specific Delivery(LSD))的抗癌前体药物,核苷环磷酸酯化合物的制备及应用,或其光学异构体、水合物、溶剂化物、可药用盐以及药物组合物。
背景技术
肝癌是发生在肝脏的原发性恶性肿瘤,常见于发生肝硬化或者肝纤维化的病人。据WHO统计,世界范围内每年因肝癌死亡的人数超过70万,肝癌是第二大致死癌症。病毒性肝炎是导致肝癌的重要诱因,亚洲和非洲因乙型和丙型病毒性肝炎流行成为肝癌最高发的地区。目前,针对肝癌的治疗是多学科的综合治疗,主要有手术、局部消融治疗、介入治疗、放疗、化疗、靶向治疗等。
目前治疗肝癌的核苷类化疗药物有限,只有氟尿嘧啶用于二线治疗,阿糖胞苷不适用于肝癌这样的实体瘤。阿糖胞苷需要在细胞内经过脱氧胞苷激酶的作用转化为单磷酸形式,再进一步磷酸化为三磷酸形式,才能抑制肿瘤细胞的DNA复制,由于实体瘤中缺乏脱氧胞苷激酶,导致实体瘤中活性成分偏少,治疗效果不佳。
本发明利用肝脏特异性递送技术,绕过了脱氧胞苷激酶磷酸化步骤,并且成功提高了肝中活性成分的浓度。
环状磷酸酯修饰的阿糖胞苷前药,在肝中经过CYP3A酶代谢,不需要脱氧胞苷激酶,生成单磷酸化合物。具体而言,环状磷酸酯(4-芳基-2-氧代-1,3,2-二氧杂磷杂环己烷)前体结构有很好的肝脏特异性递送性能,机理非常明确,即4-芳基取代位置被肝细胞中的细胞色素P450同功酶家族中的CYP3A特异性催化,生成羟基,然后开环生成带负电荷的磷酸中间体,该物质不易通过细胞膜而存在细胞内,在磷酸二酯酶催化下,经过水解,β-消除反应,生成核苷酸单磷酸化合物,继续在核苷酸激酶作用下,生成具有生物活性的核苷酸三磷酸化合物,同时,代谢副产物芳基乙烯基酮能与肝细胞中含量丰富的抗氧化和自由基的谷胱甘肽发生1,4-加成反应而被清除,尚未发现该加成产物具有副作用的报道。
阿糖胞苷毒副作用比较大,利用肝脏特异性递送技术,增强肝中浓度,有利于降低毒副作用。
目前尚缺乏活性高、肝递送性强且副作用低的抗肝脏肿瘤药物。因此,本领域迫切需要开发具有更强肝脏特异性且副作用低的高活性抗肿瘤药物。
发明内容
本发明合成了抗癌的阿糖胞苷环状磷酸酯,然后对其芳环取代基进一步的改造,得到一类更具有肝递送作用的前药,使其疗效更高,毒副作用更小的优点。
本发明的第一方面,提供了一种如式I所示的化合物,或其光学异构体、药学上可接受的盐、水合物或溶剂化物:
其中:
各个R1独自选自卤素、硝基、羟基、氨基、氰基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、-COOH、取代或未取代的C2-C6烷基羧基、取代或未取代的C2-C6酯基、取代或未取代的C2-C6烷酰基、取代或未取代的C2-C6烷酰胺基;其中,所述的取代指具有一个或多个选自下组的取代基:卤素、C1-C3烷基、C1-C3卤代烷基、硝基、羟基、氨基、氰基;
R2、R3各自独立地为卤素(F或Cl);
R4、R5各自独立地选自下组:氢、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C2-C12烷酰基、取代或未取代的C2-C11酯基(即-CO-O-C1-C10烷基);其中,所述的取代指具有一个或多个选自下组的取代基:卤素、C1-C3烷基、C1-C3卤代烷基、硝基、羟基、-NRaRb、氰基,其中Ra和Rb各自独立地为H、C1-C3烷基、C3-C6环烷基、或C1-C3卤代烷基;
m为0、1、2或3。
在另一优选例中,R4、R5各自独立地选自下组:氢、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C2-C6酯基、取代或未取代的C2-C6烷酰基;其中,所述的取代指具有一个或多个选自下组的取代基:卤素、C1-C3烷基、C1-C3卤代烷基、硝基、羟基、氨基、氰基。
且式I和式II中,除已有手性外,其他各个手性中心为R型或S型;
在另一优选例中,R2为Cl,且R3为F;或R2为Cl,且R3为Cl;或R2为F,且R3为Cl。在另一优选例中,所述的光学异构体包括互变异构体,顺反异构体,构象异构体,内消旋化合物和具有对映或非对映关系的光学异构体。
在另一优选例中,所述的化合物选自下组:
在另一优选例中,所述式I和式II所示的化合物的盐为式I和式II所示的化合物与无机酸或有机酸所形成的可药用盐,或所述式I和式II所示的化合物的盐为式I和式II所示的化合物与碱反应所形成的可药用盐。所述的式I和式II所示的化合物或其盐为无定形物或晶体。
本发明的第二方面,提供了一种药物组合物,所述的药物组合物包括治疗有效量的如本发明第一方面中所述的化合物或其光学异构体、药学上可接受的盐、水合物或溶剂化物;和药学上可接受的辅助剂、稀释剂或载体。
本发明的第三方面,提供了如本发明第一方面所述的化合物或其光学异构体、药学上可接受的盐、水合物或溶剂化物的用途,用于制备治疗和/或预防癌症,特别是肝癌的药物组合物。本发明的第四方面,提供了一种如本发明第一方面所述的式I化合物的制备方法,所述方法包括步骤:
(i-a)在惰性溶剂中,用式II化合物和酸、酰氯、卤代烷基反应,形成式I化合物;
式中,各基团的定义如上文中所述。
在另一优选例中,所述的步骤(i-a)中,所述的试剂选自下组:二环己基碳二亚胺(DCC)、三乙胺、N,N-二异丙基乙胺或其组合;优选为DCC和三乙胺。
在另一优选例中,所述的步骤(i-a)中,所述的惰性溶剂选自下组:N,N-二甲基甲酰胺、二氯甲烷、四氢呋喃或其组合;优选为N,N-二甲基甲酰胺和二氯甲烷溶剂。
在另一优选例中,所述的步骤(i-a)的反应温度为0-100℃(优选在25±5℃左右)。
在另一优选例中,所述的步骤(i-a)的去保护反应的反应时间为0.5-24小时,较佳地为0.5-8小时。
(i-b)在惰性溶剂中,用式IIa化合物脱除TBS,形成式II化合物;
在另一优选例中,所述的步骤(i-b)中,所述的脱TBS试剂选自下组:TBAF、冰醋酸、稀盐酸或其组合;优选为盐酸乙醇溶液和TBAF。
在另一优选例中,所述的步骤(i-b)中,所述的惰性溶剂选自下组:N,N-二甲基甲酰胺、四氢呋喃或其组合;优选为四氢呋喃溶剂。
在另一优选例中,所述的步骤(i-b)的反应温度为-50-30℃(优选在25±5℃左右)。
在另一优选例中,所述的步骤(i-b)的去保护反应的反应时间为0.5-6小时,较佳地为0.5-3小时,更佳地为0.5-2小时。
在另一优选例中,所述的式IIa化合物是通过以下方法制备的:
(i-c)在惰性溶剂中,将式Ic化合物与PA4101-4进行取代反应,得到式IIa化合物;
在另一优选例中,在步骤(i-c)中,所述反应在格氏试剂存在下进行;较佳地,所述的格氏试剂选自下组:叔丁基氯化镁(t-BuMgCl)。
在另一优选例中,所述的步骤(i-c)的取代反应在-50-30℃下(优选在25±5℃左右)进行。
在另一优选例中,所述的步骤(i-c)的取代反应的反应时间为1-72小时,较佳地为3-48小时,更佳地为6-24小时。
在另一优选例中,所述的步骤(i-c)的惰性溶剂选自下组:N,N-二甲基甲酰胺、四氢呋喃、或其组合;优选为四氢呋喃溶剂。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
注释:
ARA-C:阿糖胞苷,4-氨基-1-B-D-阿拉伯呋喃糖基-2(1H)-嘧啶酮(CAS:147-94-4)
ARA-CMP:4-氨基-1-B-D-5’-单磷酸阿拉伯呋喃糖基-2(1H)-嘧啶酮
具体实施方式
本发明人经过长期而深入的研究,通过对大量化合物的筛选研究,首次发现:一类具有特定结构的式I和式II化合物(其中苯环部分的2位和5位为特定的卤素),令人意外地具有非常优异的抗肝癌活性、显著提高的肝递送性以及显著降低的毒副作用。基于上述发现,发明人完成了本发明。
术语
如本文所用,术语“C1-C6烷基”指具有1~6个碳原子的直链或支链烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基,或类似基团。
如本文所用,术语“C2-C6烷酰基”指形如“具有1~6个碳原子的直链或支链烷基-羰基”结构的取代基,如乙酰基、丙酰基、丁酰基,或类似基团。
如本文所用,术语“C1-C6烷胺基”指形如“具有1~6个碳原子的直链或支链烷基-胺基”结构的取代基,如甲胺基、二甲胺基、乙胺基、丙胺基、二乙胺基,或类似基团。
术语“卤素”指F、Cl、Br和I。
本发明中,术语“含有”、“包含”或“包括”表示各种成分可一起应用于本发明的混合物或组合物中。因此,术语“主要由...组成”和“由...组成”包含在术语“含有”中。
本发明中,术语“药学上可接受的”成分是指适用于人和/或动物而无过度不良副反应(如毒性、刺激和变态反应),即有合理的效益/风险比的物质。
本发明中,术语“有效量”指治疗剂治疗、缓解或预防目标疾病或状况的量,或是表现出可检测的治疗或预防效果的量。对于某一对象的精确有效量取决于该对象的体型和健康状况、病症的性质和程度、以及选择给予的治疗剂和/或治疗剂的组合。因此,预先指定准确的有效量是没用的。然而,对于某给定的状况而言,可以用常规实验来确定该有效量,临床医师是能够判断出来的。
在本文中,除特别说明之处,术语“取代”指基团上的一个或多个氢原子被选自下组的取代基取代:卤素、C1-C3烷基、C1-C3卤代烷基、硝基、羟基、氨基、氰基。
除非特别说明,本发明中,所有出现的化合物均意在包括所有可能的光学异构体,如单一手性的化合物,或各种不同手性化合物的混合物(即外消旋体)。本发明的所有化合物之中,各手性碳原子可以任选地为R构型或S构型,或R构型和S构型的混合物。
如本文所用,术语“本发明化合物”指式I和式II所示的化合物。该术语还包括及式I和式II化合物的各种晶型形式、药学上可接受的盐、水合物或溶剂合物。
如本文所用,术语“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于:盐酸、氢溴酸、氢氟酸、硫酸、硝酸、磷酸等无机酸,甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、甲磺酸、苯甲磺酸,苯磺酸等有机酸;以及天冬氨酸、谷氨酸等酸性氨基酸。
本发明中的一些化合物可能用水或各种有机溶剂结晶或重结晶,在这种情况下,可能形成各种溶剂化物。本发明的溶剂合物包括化学计量的溶剂化物如水合物等,也包括在用低压升华干燥法制备时形成的包含可变量水的化合物。
应理解,本发明的化合物制备后可能存在各种热力学稳定的异构体,如互变异构体、构象异构体、内消旋化合物和具有对映或非对映关系的光学异构体等,上述改变形式在阅读了本发明的公开之后,对于本领域技术人员而言是显而易见的。
式I化合物及其制备
为了提供一种能够通过肝递送机制,让抗癌的核苷酸类药物集中在肝细胞中释放的高效、低毒的肝递送前体药物,发明人制备了式I化合物:
其中:
各R1独自选自卤素、硝基、羟基、氨基、氰基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C1-C6羧基、取代或未取代的C1-C6酯基、取代或未取代的C2-C6烷酰基、取代或未取代的C2-C6烷酰胺基;其中,所述的取代指具有一个或多个选自下组的取代基:卤素、C1-C3烷基、C1-C3卤代烷基、硝基、羟基、氨基、氰基;
m为0、1、2或3;
R2、R3各自独立地为卤素(F或Cl);
R4、R5独自选自氢、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C1-C6酯基、取代或未取代的C2-C6烷酰基;其中,所述的取代指具有一个或多个选自下组的取代基:卤素、C1-C3烷基、C1-C3卤代烷基、硝基、羟基、氨基、氰基;
且式I中,除已有手性外,其他各个手性中心为R型或S型。
所述的化合物可以是消旋体,或为光学异构体,两者皆具有一定的肝癌治疗活性。优选的所述的式I化合物具有选自下组的结构:
在另一优选例中,所述的P2与磷酸酯环结构中4位的芳香基团互为顺式,且P2为R构型,C4为S型。
在另一优选例中,R2为Cl,且R3为F;或R2为Cl,且R3为Cl;或R2为F,且R3为Cl。
在另一优选例中,所述的光学异构体包括互变异构体,顺反异构体,构象异构体,内消旋化合物和具有对映或非对映关系的光学异构体。
在另一优选例中,所述的化合物选自下组:
通式I化合物的制备方法如下:
在四氢呋喃溶液中,加入PA4101-4化合物,然后0℃下,滴加叔丁基氯化镁,反应30分钟,然后一次性加入Ic化合物,反应过夜,淬灭,硅胶柱层析纯化,得中间体IIa,IIa加入盐酸乙醇溶液,脱去保护基TBS,得通式IIa化合物,II和酸、酰氯、卤代烷基反应得通式I化合物。
其中,各个反应物可以通过市售途径购得,也可以采用市售的原料,通过本领域常规的方法制备。
药物组合物和施用方法
由于本发明化合物具有优异的对肝癌的抑制活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物可用于治疗、预防以及缓解癌症,特别是肝癌及其相关的症状。。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有0.1-1000mg本发明化合物/剂,更佳地,含有0.5~500mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如吐温)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。特别优选的施用方式是口服。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药,或者与其他药学上可接受的化合物联合给药。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为0.2~1000mg,优选0.5~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
本发明的主要优点包括:
(1)肝递送性高,化合物只能被肝细胞中的细胞色素P450同功酶家族中的CYP3A特异性催化,生成活性分子,该活性分子带高负电荷,不容易排出肝外,所以在肝中浓度更高,达到肝递送效果。
(2)活性高,因为肝递送性,所以更多的药物存在肝中,抗癌活性也能大大的提高。
(3)毒副作用低:同等剂量的前药,在肝外代谢成活性分子的量很少,所以对肾脏、骨髓等主要脏器的毒性大大降低。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
实施例1 PA4101
合成路线:
实验部分:
步骤1)化合物PA4101-2的合成:
化合物PA4101-1(Cytarbine,9.5g,39mmol)和咪唑(18g,264mmol)溶于DMF(100mL)中,加入4-二甲氨基吡啶((DMAP,3.8g,31mmol),在冰浴下慢慢加入叔丁基二甲基氯硅烷(TBSCl,30g,198mmol),氮气保护下,反应在63℃搅拌过夜,反应结束后,反应液缓慢加入水(400mL)中,乙酸乙酯(3×300mL)萃取,饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,硅胶柱层析分离纯化得PA4101-2(20.6g),产率90%。
步骤2)化合物PA4101-3的合成:
化合物PA4101-2(20.6g,35.2mmol)溶于0.5%的盐酸乙醇溶液(610mL)中,反应液在室温下搅拌4.5小时后(TLC或LCMS跟踪,反应完全),用饱和NaHCO3溶液中和,旋蒸去除乙醇,加入水(200mL),用乙酸乙酯(3×200mL)萃取,无水硫酸钠干燥,过滤,旋干,硅胶柱层析分离纯化(洗脱剂为:PE:EA:CH3OH(V∶V)=150∶150∶4.5)得到白色固体化合物PA4101-3(14.7g),产率89%。
步骤3)化合物PA4101-4的合成:
化合物PA4101-3(14.7g,31.2mmol)溶于吡啶溶剂(50mL)中,加入N,N-二甲基甲酰胺甲缩醛(4.83g,40.5mmol),反应在室温下搅拌过夜,旋蒸去除吡啶,得粗品,硅胶柱层析分离纯化(洗脱剂:二氯甲烷∶甲醇(V∶V)=100∶3)得到白色固体化合物PA4101-4(13.0g),产率79%。
步骤4)化合物PA4101-6的合成:
化合物PA4101-4(6.7g,12.7mmol)在氮气保护下溶于四氢呋喃(130mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(50.0mL,50mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4101-5(6.4g,16.5mmol),室温下搅拌反应12h,反应结束后用饱和氯化铵溶液(50mL)淬灭,乙酸乙酯(3×200mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4101-6(6.15g),产率67%。
步骤5)化合物PA4101的合成:
化合物PA4101-6(11.5g,16mmol)溶于12%的盐酸乙醇溶液中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(100mL),用乙酸乙酯(3×100mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4101(4.5g),产率57%。
实施例2 PA4102(对比例)
合成路线:
实验部分:
步骤1)化合物PA4102-2的合成:
化合物PA4101-4(2.79g,5.3mmol)在氮气保护下溶于四氢呋喃(60mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(26.0mL,26.0mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4102-1(2.13g,6.3mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(30mL)淬灭反应,乙酸乙酯(3×150mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4102-2(0.68g),产率19.2%。
步骤2)目标化合物PA4102的合成:
化合物PA4102-2(0.68g,1mmol)溶于3.6%的盐酸乙醇溶液(15mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(50mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4102(300mg),产率71%。
实施例3 PA4103
合成路线:
实验部分:
步骤1)化合物PA4103-2的合成:
化合物PA4101-4(0.37g,0.7mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(2.8mL,2.8mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4103-1(0.38g,0.94mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(10mL)淬灭反应,乙酸乙酯(3×25mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4103-2(0.17g),产率32%。
步骤2)目标化合物PA4103的合成:
化合物PA4103-2(0.17g,0.28mmol)溶于3.6%的盐酸乙醇溶液(4mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(15mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4103(46mg),产率39%。
实施例4 PA4104
合成路线:
实验部分:
步骤1)化合物PA4104-2的合成:
化合物PA4101-4(0.37g,0.7mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(2.8mL,2.8mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4104-1(0.38g,0.94mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(10mL)淬灭反应,乙酸乙酯(3×25mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4104-2(0.32g),产率65%。
步骤2)目标化合物PA4104的合成:
化合物PA4104-2(0.32g,0.46mmol)溶于3.6%的盐酸乙醇溶液(7mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(25mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4104(43mg),产率20%。
实施例5 PA4105
合成路线:
实验部分:
步骤1)化合物PA4105-2的合成:
化合物PA4101-4(0.33g,0.64mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(2.5mL,2.5mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4105-1(0.38g,0.94mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(10mL)淬灭反应,乙酸乙酯(3×25mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4105-2(0.1g),产率22%。
步骤2)目标化合物PA4105的合成:
化合物PA4105-2(0.1g,0.14mmol)溶于3.6%的盐酸乙醇溶液(3mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(10mL),用乙酸乙酯(3×40mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4105(17mg),产率24.5%。
实施例6 PA4106
合成路线:
实验部分:
步骤1)化合物PA4106-2的合成:
化合物PA4101-4(0.33g,0.64mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(2.5mL,2.5mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4106-1(0.38g,0.94mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(10mL)淬灭反应,乙酸乙酯(3×25mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4106-2(0.22g),产率48%。
步骤2)目标化合物PA4106的合成:
化合物PA4106-2(0.22g,0.3mmol)溶于3.6%的盐酸乙醇溶液(5mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(20mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4106(45mg),产率30%。
实施例7 PA4107
合成路线:
实验部分:
步骤1)化合物PA4107-2的合成:
化合物PA4101-4(0.35g,0.66mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(2.7mL,2.7mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4107-1(0.38g,0.94mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(10mL)淬灭反应,乙酸乙酯(3×25mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4107-2(0.29g),产率61.7%。
步骤2)目标化合物PA4107的合成:
化合物PA4107-2(0.29g,0.39mmol)溶于3.6%的盐酸乙醇溶液(5mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(20mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4107(90mg),产率47%。
实施例8 PA4108
合成路线:
实验部分:
步骤1)化合物PA4108-2的合成:
化合物PA4101-4(380mg,0.72mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(3mL,3mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4108-1(0.32g,0.86mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(15mL)淬灭反应,乙酸乙酯(3×150mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4108-2(140mg),产率27%。
步骤2)目标化合物PA4108的合成:
化合物PA4108-2(140mg,0.19mmol)溶于3.6%的盐酸乙醇溶液(3mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(50mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4108(35mg),产率36%。
实施例9 PA4109
合成路线:
实验部分:
步骤1)化合物PA4109-2的合成:
化合物PA4101-4(380mg,0.72mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(3mL,3mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4109-1(350mg,0.86mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(30mL)淬灭反应,乙酸乙酯(3×150mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4109-2(310mg),产率58.4%。
步骤2)目标化合物PA4109的合成:
化合物PA4109-2(310mg,0.42mmol)溶于3.6%的盐酸乙醇溶液(3mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(50mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4109(110mg),产率52%。
实施例10 PA4110
合成路线:
实验部分:
步骤1)化合物PA4110-2的合成:
化合物PA4101-4(330mg,0.6mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(3mL,3mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4110-1(0.3g,0.8mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(30mL)淬灭反应,乙酸乙酯(3×150mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4110-2(200mg),产率45%。
步骤2)目标化合物PA4110的合成:
化合物PA4110-2(200mg,0.28mmol)溶于3.6%的盐酸乙醇溶液(3mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(50mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4110(70mg),产率52%。
实施例11 PA4111
合成路线:
实验部分:
步骤1)化合物PA4111-2的合成:
化合物PA4101-4(200mg,0.38mmol)在氮气保护下溶于四氢呋喃(10mL)中,冰浴冷却至0℃,缓慢滴加1M的叔丁基氯化镁溶液(1.4mL,1.4mmol),滴加完毕后,反应液在室温下搅拌1小时,再冷却到0℃,加入PA4111-1(211mg,0.57mmol),室温下搅拌过夜,反应结束后用饱和氯化铵溶液(30mL)淬灭反应,乙酸乙酯(3×150mL)萃取,饱和食盐水洗,无水硫酸钠干燥,旋干,硅胶柱层析分离纯化得白色固体化合物PA4111-2(100mg),产率34%。
步骤2)目标化合物PA4111的合成:
化合物PA4111-2(230mg,0.31mmol)溶于3.6%的盐酸乙醇溶液(15mL)中,室温下搅拌反应过夜。TLC显示反应完毕后,用氨水调pH值至8-9,旋蒸去除乙醇后加水(50mL),用乙酸乙酯(3×50mL)萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,旋干,通过Combiflash色谱柱纯化,得白色固体PA4111(30mg),产率48%。
表1各个实施例中所制备得到的化合物如下表中所示
/>
/>
表2各个实施例中所制备得到的化合物核磁如下表中所示
实施例12体外重组人CYP3A4代谢的评价
测定方法:
1)试剂来源
重组人CYP3A4酶购自BD公司,批号3100772。
测试化合物PA4101、PA4102、PA4103、PA4104、PA4105、PA4106、PA4107、PA4108、PA4109、PA4110和PA4111由浙江柏拉阿图医药科技有限公司合成,溶解于甲醇(国药试剂),制成浓度为100μM的存储液。
2)反应过程
酶促反应在100mM KH2PO4缓冲溶液(pH 7.4)中进行,测试化合物浓度为100nM,人肝微粒体浓度为0.1nmol/ml,NADPH浓度为2mM。反应由最后加入的NADPH启动,在恒温震荡水浴锅内反1,5,10,20,30min后取样,立即加入1.5倍体积的甲醇以终止反应。
3)样品处理和分析方法
I样品前处理:
用Eppendorf台式离心机以最大转速13,600rpm离心20分钟。取上清液,用氮吹仪吹干之后重新溶解至流动相A(0.1%甲酸v/v的水溶液)。
II液相梯度:
分析柱:Waters,Acquity UPLC HSS T3 column
流速:0.5ml/min
柱温:45摄氏度
III质谱条件
离子源为电喷雾电离源(Turbo Ionspray);正离子模式;毛细管电压为3.0kV;温度为500℃;去溶剂气流1000L/h;扫描时间、锥孔电压、碰撞能量及用于定量分析的离子反应见下表(表3):
表3,各分析物质谱条件
分析物 | Q1(m/z) | Q3(m/z) | Dwell(s) | Cone(V) | Collision(V) |
PA4101 | 492 | 169 | 0.1 | 24 | 22 |
PA4102 | 441 | 330 | 0.1 | 32 | 12 |
PA4103 | 508 | 185 | 0.1 | 38 | 22 |
PA4104 | 476 | 153 | 0.1 | 28 | 26 |
PA4105 | 492 | 169 | 0.1 | 18 | 20 |
PA4106 | 492 | 169 | 0.1 | 28 | 22 |
PA4107 | 492 | 169 | 0.1 | 36 | 18 |
PA4108 | 492 | 169 | 0.1 | 32 | 26 |
PA4109 | 508 | 185 | 0.1 | 32 | 20 |
PA4110 | 476 | 153 | 0.1 | 16 | 22 |
PA4111 | 476 | 153 | 0.1 | 28 | 18 |
表4体外重组人CYP3A4酶清除速率
结果表明:在体外,所有化合物均被重组人CYP3A4酶清除,不同化合物的清除速率存在显著差异。出乎意料的是PA4109、PA4108和PA4101清除的速率远远高于PA4102(目前临床三期)。其中PA4109、PA4108和PA4101的转化速率分别约是PA4102的20.6倍、7.24倍和10.7倍(表4),清除速率越高,生成活性单磷酸代谢产物就越多,就能产生更强的药理活性。
综上,由于本发明式I和式II化合物具有更高的活性,因此治疗时所需的用量更低,具有更高的安全性和更低的毒副作用。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (9)
1.一种如下式I所示的化合物,或其药学上可接受的盐:
其中,所述的化合物具有选自下组的结构:
2.如权利要求1所示的化合物,或其药学上可接受的盐,其特征在于,所述的化合物为:
3.如权利要求1所述的化合物,或其药学上可接受的盐,其特征在于,所述式I和式II所示的化合物的盐为式I和式II所示的化合物与无机酸或有机酸所形成的可药用盐,或所述式I和式II所示的化合物的盐为式I和式II所示的化合物与碱反应所形成的可药用盐;所述的式I和式II所示的化合物或其盐为无定形物或晶体。
4.一种药物组合物,其特征在于,所述的药物组合物包括治疗有效量的如权利要求1中所述的化合物或其药学上可接受的盐;和药学上可接受的辅助剂、稀释剂或载体。
5.如权利要求1所述的化合物或其药学上可接受的盐的用途,其特征在于,用于制备治疗和/或预防癌症的药物组合物。
6.如权利要求5所述的用途,其特征在于,所述的癌症为肝癌。
7.如权利要求1所述的式I化合物的制备方法,其特征在于,包括步骤:
(i-a)在惰性溶剂中,用式II化合物和酸、酰氯、卤代烷基反应,形成式I化合物;
式中,各基团的定义如权利要求1中所述。
8.如权利要求7所述的制备方法,其特征在于,所述的式II化合物是通过以下方法制备的:
(i-b)在惰性溶剂中,用式IIa化合物脱除TBS,形成式II化合物;
式中,各基团的定义如权利要求1中所述。
9.如权利要求8所述的制备方法,其特征在于,所述的式IIa化合物是通过以下方法制备的:
(i-c)在惰性溶剂中,将式Ic化合物与PA4101-4进行取代反应,得到式IIa化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017114089423 | 2017-12-22 | ||
CN201711408942.3A CN109956985A (zh) | 2017-12-22 | 2017-12-22 | 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 |
PCT/CN2018/122822 WO2019120300A1 (zh) | 2017-12-22 | 2018-12-21 | 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111655703A CN111655703A (zh) | 2020-09-11 |
CN111655703B true CN111655703B (zh) | 2023-07-25 |
Family
ID=66993985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711408942.3A Pending CN109956985A (zh) | 2017-12-22 | 2017-12-22 | 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 |
CN201880088159.XA Active CN111655703B (zh) | 2017-12-22 | 2018-12-21 | 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711408942.3A Pending CN109956985A (zh) | 2017-12-22 | 2017-12-22 | 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10899787B2 (zh) |
EP (1) | EP3730504B1 (zh) |
JP (1) | JP2021506841A (zh) |
CN (2) | CN109956985A (zh) |
ES (1) | ES2958817T3 (zh) |
TW (1) | TWI772583B (zh) |
WO (1) | WO2019120300A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109956986B (zh) * | 2017-12-22 | 2021-04-27 | 浙江柏拉阿图医药科技有限公司 | 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101252839A (zh) * | 2005-08-12 | 2008-08-27 | 默克公司 | 新的2′-c-甲基和4′-c-甲基核苷衍生物 |
CN102164939A (zh) * | 2007-11-29 | 2011-08-24 | 配体制药公司 | 抗病毒的核苷化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL212929B1 (pl) * | 2002-10-31 | 2012-12-31 | Metabasis Therapeutics Inc | Pochodna cytarabiny, jej zastosowania oraz kompozycja farmaceutyczna zawierajaca ta pochodna |
JP2009504677A (ja) * | 2005-08-12 | 2009-02-05 | メルク・エンド・カムパニー・インコーポレーテツド | 新規2’−c−メチル及び4’−c−メチルヌクレオシド誘導体 |
BRPI0821106A2 (pt) * | 2007-11-29 | 2015-06-16 | Ligand Pharm Inc | Pró-fármacos de nucleosídeo e usos dos mesmos |
CN103393709B (zh) | 2013-08-12 | 2014-03-19 | 西安新通药物研究有限公司 | 阿糖胞苷前药制药用途 |
US10899788B2 (en) | 2016-06-20 | 2021-01-26 | Merck Sharp & Dohme Corp. | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
-
2017
- 2017-12-22 CN CN201711408942.3A patent/CN109956985A/zh active Pending
-
2018
- 2018-12-21 JP JP2020533228A patent/JP2021506841A/ja active Pending
- 2018-12-21 WO PCT/CN2018/122822 patent/WO2019120300A1/zh unknown
- 2018-12-21 ES ES18892537T patent/ES2958817T3/es active Active
- 2018-12-21 CN CN201880088159.XA patent/CN111655703B/zh active Active
- 2018-12-21 TW TW107146533A patent/TWI772583B/zh active
- 2018-12-21 EP EP18892537.4A patent/EP3730504B1/en active Active
-
2020
- 2020-06-20 US US16/907,215 patent/US10899787B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101252839A (zh) * | 2005-08-12 | 2008-08-27 | 默克公司 | 新的2′-c-甲基和4′-c-甲基核苷衍生物 |
CN102164939A (zh) * | 2007-11-29 | 2011-08-24 | 配体制药公司 | 抗病毒的核苷化合物 |
Non-Patent Citations (1)
Title |
---|
Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-D-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma;Serge H. Boyer,等;《J. Med. Chem.》;20061221;第7711-7720页 * |
Also Published As
Publication number | Publication date |
---|---|
JP2021506841A (ja) | 2021-02-22 |
EP3730504C0 (en) | 2023-07-12 |
US10899787B2 (en) | 2021-01-26 |
CN109956985A (zh) | 2019-07-02 |
EP3730504A4 (en) | 2021-07-28 |
ES2958817T3 (es) | 2024-02-15 |
EP3730504A1 (en) | 2020-10-28 |
TW201927308A (zh) | 2019-07-16 |
TWI772583B (zh) | 2022-08-01 |
WO2019120300A1 (zh) | 2019-06-27 |
EP3730504B1 (en) | 2023-07-12 |
US20200317711A1 (en) | 2020-10-08 |
CN111655703A (zh) | 2020-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200317713A1 (en) | Liver specific delivery-based entecavir prodrug, nucleoside cyclic phosphate compound, and application thereof | |
KR102434764B1 (ko) | 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용 | |
US10913765B2 (en) | Liver specific delivery-based gemcitabine prodrug nucleoside cyclic phosphate compound, and application thereof | |
CN111655703B (zh) | 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用 | |
KR102619437B1 (ko) | 젬시타빈의 인-함유 프로드러그 | |
CN108727450B (zh) | 肝递送抗丙肝前体药物核苷环磷酸酯化合物及应用 | |
CN117658983A (zh) | 选择性parp1抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |